Oskar Hansson
Fondateur chez Cell Invent Sweden AB
Profil
Mr. Oskar Hansson is an Investment Associate at Abelco Investment Group and a Scientific Advisor at Cell Invent Sweden AB.
He received his graduate degree from Umea Universitet.
Postes actifs de Oskar Hansson
| Sociétés | Poste | Début |
|---|---|---|
Cell Invent Sweden AB
 Cell Invent Sweden AB Miscellaneous Commercial ServicesCommercial Services Cell Invent Sweden AB is a company based in Lund, Sweden that develops new human disease models based on reprogrammed Alzheimer patient cells. The Swedish company is developing phenotype-based screening methods for drug discovery, drug development, and companion diagnostics development. The company was founded in 2019 by Håkan Toresson, Camilla Orbjörn, Lennart Minthon, Oskar Hansson, and Håkan Toresson has been the CEO since 2019. | Fondateur | 01/01/2019 |
Abelco Investment Group (Private Equity)
 Abelco Investment Group (Private Equity) Investment ManagersFinance Abelco Investment Group (Private Equity) (Abelco Investment Group) is a private equity of Abelco Investment Group AB founded in 2009. The firm is headquartered in Stockholm, Sweden. | Analyste en capital-investissement | 01/06/2021 |
Formation de Oskar Hansson
| Umea Universitet | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Abelco Investment Group (Private Equity)
Abelco Investment Group (Private Equity) Investment ManagersFinance Abelco Investment Group (Private Equity) (Abelco Investment Group) is a private equity of Abelco Investment Group AB founded in 2009. The firm is headquartered in Stockholm, Sweden. | Finance |
Cell Invent Sweden AB
Cell Invent Sweden AB Miscellaneous Commercial ServicesCommercial Services Cell Invent Sweden AB is a company based in Lund, Sweden that develops new human disease models based on reprogrammed Alzheimer patient cells. The Swedish company is developing phenotype-based screening methods for drug discovery, drug development, and companion diagnostics development. The company was founded in 2019 by Håkan Toresson, Camilla Orbjörn, Lennart Minthon, Oskar Hansson, and Håkan Toresson has been the CEO since 2019. | Commercial Services |